Physician profile
Michael Stern
NPI 1356737134
$6,534.16
in general payments reported to CMS, 2019-2025
47 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $255 · 2021: $420 · 2022: $1,113 · 2023: $1,644 · 2024: $1,522 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,111 · Travel and Lodging: $566 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,111.19 |
| Travel and Lodging | $565.64 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $810.13 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Biotech, INC. | $567.40 | 2022-2025 | Erleada, Tremfya |
| Astellas Pharma US INC | $472.37 | 2020-2024 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $432.54 | 2025 | |
| Abbvie INC. | $327.75 | 2020-2025 | Botox |
| Sumitomo Pharma America, INC. | $278.06 | 2023-2025 | Orgovyx, Gemtesa |
| Merck Sharp & Dohme LLC | $259.18 | 2021-2025 | Keytruda, Welireg, Keytruda Qlex |
| Urogen Pharma, INC. | $248.29 | 2022-2025 | Jelmyto |
| Pfizer INC. | $247.81 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.36 | 2020-2025 | |
| C. R. Bard, INC. & Subsidiaries | $240.93 | 2024 | Bard Urinary Drainage Bag |
| Olympus Corporation of The Americas | $206.27 | 2023 | Hd Camera Head, Oes Cystonephrofiberscope, Cysto-Nephro Videoscope |
| Halozyme INC | $193.79 | 2023 | |
| Urovant Sciences INC | $176.93 | 2022 | |
| Endo Pharmaceuticals INC. | $169.73 | 2020-2024 | Xiaflex |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $167.75 | 2023-2025 | Prolaris, Myrisk |
| Medtronic, INC. | $116.12 | 2021-2025 | Interstim |
| Endo USA, INC. | $108.69 | 2025 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $103.38 | 2021-2023 | Saphnelo, Lynparza |
| Telix Pharmaceuticals | $99.78 | 2024-2025 | Illuccix |
| 180 Medical, INC. | $96.05 | 2020-2025 | Gentlecath |
| Progenics Pharmaceuticals, INC. | $85.42 | 2023-2025 | Pylarify |
| Abc Home Medical Supply, INC. | $77.26 | 2024-2025 | |
| Ardelyx, INC. | $73.04 | 2022-2024 | Ibsrela |
| Boston Scientific Corporation | $66.97 | 2023 | Ams 700 Cxr Rte Kit |
| Hollister Incorporated | $59.37 | 2024 | Vapro Plus Pocket, Infyna Chic |
| Takeda Pharmaceuticals U.S.A., INC. | $57.40 | 2023-2025 | Entyvio |
| Teleflex LLC | $50.26 | 2025 | Barrigel |
| Ferring Pharmaceuticals INC. | $44.75 | 2024-2025 | Adstiladrin |
| Aimmune Therapeutics, INC. | $44.25 | 2024 | |
| Axonics, INC. | $33.79 | 2020 | |
| Allergan, INC. | $32.30 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $31.90 | 2022-2025 | Provenge |
| Blue Earth Diagnostics | $28.16 | 2024 | |
| Acerus Pharmaceuticals Corporation | $27.93 | 2021 | |
| Amgen INC. | $27.91 | 2022-2023 | Prolia, Evenity |
| Olympus America INC. | $27.46 | 2024 | Itind System |
| Rochester Medical Corporation | $26.11 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $21.96 | 2025 | |
| Kerecis Limited | $21.46 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Phathom Pharmaceuticals, INC. | $21.18 | 2024 | Voquezna |
| Myovant Sciences INC. | $20.93 | 2022 | |
| Neotract INC. | $19.57 | 2020 | |
| Tolmar, INC. | $18.31 | 2023 | |
| Immunitybio, INC. | $17.29 | 2024 | |
| Medtronic USA, INC. | $17.25 | 2020 | |
| Alfasigma USA, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.